Moderna (MRNA) announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with ...
RNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and ...
ROS are key players in the immune system's response to infection and cancer, influencing how the body identifies and fights these threats. A balanced level of ROS supports healthy immune function, but ...
Hosted on MSN
Basal cell carcinoma's low immunogenicity linked to suppression of antigen presentation from its cell of origin
Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune-based therapies). Despite harboring the highest tumor mutational burden of ...
Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial This is an ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely targets tumors, today announced an ...
Vaccination against viruses commonly uses viral proteins to induce an immune response. The vaccine presents the viral proteins as the antigen to which the immune system responds. During natural viral ...
ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced novel data and patent filing today on the unanticipated finding that multiple microinjections of myelin basic ...
In a recent article posted to the bioRxiv* preprint server, researchers analyzed the influence of multiple shots of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Wuhan strain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback